Business Context and Reporting Period
This Form 8-K was filed by Vanda Pharmaceuticals Inc. on January 24, 2014. The report discloses the entry into a Material Definitive Agreement with Patheon Pharmaceuticals Inc. regarding the commercial manufacturing of the Company's product, HETLIOZ® (tasimelteon).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement rather than financial performance data.
Material Changes
The primary material change is the execution of a Manufacturing Agreement with Patheon Pharmaceuticals Inc. Key terms include:
- Scope: Manufacture of commercial supplies of HETLIOZ® 20 mg capsules at Patheon's Cincinnati, Ohio site.
- Responsibilities: Vanda supplies the active pharmaceutical ingredient (API) and meets minimum yearly order requirements. Patheon handles manufacturing, quality control, stability testing, and packaging.
- Term: Initial term of five years with automatic renewal for successive one-year terms unless terminated with at least twelve months' notice.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard termination clauses of the agreement. The agreement includes provisions allowing either party to terminate under certain circumstances upon specified written notice.
Investor Verification Checklist
- Verify the full text of the Manufacturing Agreement in the exhibits to the Form 10-Q for the quarter ending March 31, 2014.
- Confirm the specific "minimum yearly order requirements" Vanda has agreed to, as these impact future cash outflows.
- Monitor the operational status of Patheon's Cincinnati, Ohio manufacturing site.
- Review subsequent filings for any updates on the commercial launch timeline of HETLIOZ®.